Most of the patients carrying a mutation in KCNC2 suffer from a severe, drug-resistant developmental and epileptic encephalopathy starting before the first year of age associated to a de novo mutations. Additionally, there are likely pathogenic variants described which are associated to more benign phenotypes like genetic generalized epilepsy.
KCNC2